According to the Zhitong Finance App, Tianjin Development (00882.HK) announced Lisheng Pharmaceutical's results for the nine months ended September 30, 2026, with total operating revenue of 888 million yuan, a year-on-year decrease of 11.84%; net profit attributable to owners of the parent company was 78.51 million yuan, a year-on-year decrease of 78.82%; and basic earnings per share were 0.25 yuan.

According to the Zhitong Finance App, Tianjin Development (00882.HK) announced Lisheng Pharmaceutical's results for the nine months ended September 30, 2026, with total operating revenue of 888 million yuan, a year-on-year decrease of 11.84%; net profit attributable to owners of the parent company was 78.51 million yuan, a year-on-year decrease of 78.82%; and basic earnings per share were 0.25 yuan.